Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta's Duchenne Drug Gains New Panel Review Date, Maybe Optimism

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reschedules eteplirsen's advisory committee meeting for April 25.

You may also be interested in...



Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access

Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.

Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups

Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel